"First in a series of milestones," says new President.
MISSISSAUGA, ON, May 20 /CNW/ - MedX Health Corp. (TSXV: MDX) ("MedX" or the "Company") is pleased to announce that it has filed a Provisional Patent Application with the U.S. Patent Office for its "Photobandage(TM)", a novel bandage technology designed to enhance the healing process by bathing the area surrounding a wound in light.
"We are very pleased to announce this filing," said MedX President Steve Guillen. "We have said publicly that it is our intention to accelerate the development of this new product, aimed at the large and rapidly-growing wound care market. This filing, the first in what will be a series of event/milestones, is evidence of progress in this direction and of our commitment to the application of light therapy to the wound-care market. As stated before, the Company intends to license this new technology to one or more major wound care companies for further development, marketing and sales."
About MedX Health Corp.
MedX is a leading North American developer and manufacturer of phototherapy (Low Level Laser) medical devices, including dental, rehabilitation and wound care products. MedX products are used by practitioners in clinics, academic facilities, and hospitals throughout North America, as well as by professional athletes and sports teams, to improve quality of life through accelerating healing and reducing pain. MedX plans to use the proceeds from its recent public offering to expand its distribution network; support its marketing program; continue development of new dental, rehabilitation and wound care products; undertake research and development for wound care products; and for working capital purposes.
The TSX Venture Exchange does not accept responsibility for the adequacy
or accuracy of this press release.
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Such forward-looking information may include statements regarding the Company's future plans, objectives, performance, growth, profits, operating expenses or its underlying assumptions. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects", or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "does not anticipate", or "believes" or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", or "will be taken", "occur", or "be achieved". Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of MedX to be materially different from those expressed or implied by such forward-looking information, including uncertainty of successful development of new products, uncertainty of successful manufacturing or marketing of products, uncertainty of commercial acceptance of products, uncertainty concerning governmental regulation, dependency on key employees and relationships, rapid technological changes, foreign currency fluctuations. MedX does not undertake to update any forward-looking information, except in accordance with applicable securities laws.
%SEDAR: 00017466E